The effect of dill powder on the treatment of type 2 diabetic patients

Assessment of the effect of dill powder on gastrointestinal symptoms, glycemic control, lipid profile, serum levels of oxidant and Inflammatory markers in type 2 diabetic patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120704010181N12

Enrollment

Registered

2018-05-12

Start date

2018-01-20

Completion date

Unknown

Last updated

2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes. Diabetes mellitus

Interventions

Intervention 1: Dill powder, 1 gram , three capsule per day for 8 weeks. Intervention 2: placebo, 1 gram , three capsule per day for 8 weeks.

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetic Body mass index between 25-35 Age between 30-60 years Desire to collaborate on the research project

Exclusion criteria

Exclusion criteria: Having other endocrine diseases, cardiovascular, liver, kidney, thyroid Taking steroids or hormone medications, consumption vitamin , herbal, mineral or, antioxidants supplements in the last three months Having physical activity Weight loss diet pregnancy lactation

Design outcomes

Primary

Measure	Time frame
Fasting Glucose. Timepoint: baseline, 8 weeks after intervention period. Method of measurement: Fasting serum Glucose concentration in mg/dl by kit.;Serum levels of insulin. Timepoint: baseline, 8 weeks after intervention period. Method of measurement: Fasting serum Insulin concentration in µU/ml by kit.;Serum Fructosamine. Timepoint: baseline, 8 weeks after intervention period. Method of measurement: Fasting serum Fructosamine concentration in µmol/L by kit.;Serum cholestrol. Timepoint: baseline, 8 weeks after intervention period. Method of measurement: Fasting Serum cholestrol concentration in mg/dl by kit.;LDL Cholestrol. Timepoint: baseline, 8 weeks after intervention period. Method of measurement: Fasting Serum HDL Cholestrol concentration in mg/dl, calculating by Friedewald formula.;HDL Cholestrol. Timepoint: baseline, 8 weeks after intervention period. Method of measurement: Fasting Serum HDL Cholestrol concentration in mg/dl by kit.;Serum Teriglycerid. Timepoint: baseline, 8 weeks after intervention period. Method of measurement: Fasting serum Teriglycerid concentration in mg/dl by kit.;Hs- CRP. Timepoint: baseline, 8 weeks after intervention period. Method of measurement: serum hs- CRP concentration in mg/L by kit.;Serum malondialdehyde. Timepoint: baseline, 8 weeks after intervention period. Method of measurement: Fasting serum malondialdehyde concentration in µmol/ml by kit.;Total Antioxidant Capacity. Timepoint: baseline, 8 weeks after intervention period. Method of measurement: Fasting serum Total Antioxidant Capacity in U/ml by kit.;Gastrointestinal symptoms. Timepoint: baseline, 8 weeks after intervention period. Method of measurement: Using the questionnaire by percentage.	—

Measure

Time frame

Fasting Glucose. Timepoint: baseline, 8 weeks after intervention period. Method of measurement: Fasting serum Glucose concentration in mg/dl by kit.;Serum levels of insulin. Timepoint: baseline, 8 weeks after intervention period. Method of measurement: Fasting serum Insulin concentration in µU/ml by kit.;Serum Fructosamine. Timepoint: baseline, 8 weeks after intervention period. Method of measurement: Fasting serum Fructosamine concentration in µmol/L by kit.;Serum cholestrol. Timepoint: baseline, 8 weeks after intervention period. Method of measurement: Fasting Serum cholestrol concentration in mg/dl by kit.;LDL Cholestrol. Timepoint: baseline, 8 weeks after intervention period. Method of measurement: Fasting Serum HDL Cholestrol concentration in mg/dl, calculating by Friedewald formula.;HDL Cholestrol. Timepoint: baseline, 8 weeks after intervention period. Method of measurement: Fasting Serum HDL Cholestrol concentration in mg/dl by kit.;Serum Teriglycerid. Timepoint: baseline, 8 weeks after intervention period. Method of measurement: Fasting serum Teriglycerid concentration in mg/dl by kit.;Hs- CRP. Timepoint: baseline, 8 weeks after intervention period. Method of measurement: serum hs- CRP concentration in mg/L by kit.;Serum malondialdehyde. Timepoint: baseline, 8 weeks after intervention period. Method of measurement: Fasting serum malondialdehyde concentration in µmol/ml by kit.;Total Antioxidant Capacity. Timepoint: baseline, 8 weeks after intervention period. Method of measurement: Fasting serum Total Antioxidant Capacity in U/ml by kit.;Gastrointestinal symptoms. Timepoint: baseline, 8 weeks after intervention period. Method of measurement: Using the questionnaire by percentage.

—

Secondary

Measure	Time frame
Body Mass Index. Timepoint: baseline, 8 weeks after intervention period. Method of measurement: body weight / hight square (kg/m2).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGolnaz Amoohi Foroushani

Ahvaz University of Medical Sciences

Golnazamoochi@gmail.com+98 61 3221 1503

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 18, 2026